News - Herceptin, Tarceva

Filter

Current filters:

HerceptinTarceva

Popular Filters

1 to 25 of 59 results

EMA says that vials of falsified Herceptin have been identified

EMA says that vials of falsified Herceptin have been identified

16-04-2014

The European Medicines Agency says it has been informed that vials of Swiss drug major Roche’s blockbuster…

EuropeHealthcareHerceptinOncologyPharmaceuticalRegulationRoche

UK’s NICE reverses negative decision on Roche’s Tarceva for NSCLC

04-04-2014

Following a consultation period, the UK drug watchdog the National Institute for Health and Care Excellence…

Northern EuropeOncologyPharmaceuticalPricingRegulationRocheTarcevaUK

UK’s NICE consults on updating guidance for Tarceva and Iressa

UK’s NICE consults on updating guidance for Tarceva and Iressa

04-02-2014

The UK’s National Institute for Health and Care Excellence (NICE) said this morning that it is reviewing…

AstraZenecadocetaxelIressaOncologyPharmaceuticalRegulationRocheTarcevaUK

Mylan debuts Hertraz, first Herceptin biosimilar, in India

Mylan debuts Hertraz, first Herceptin biosimilar, in India

03-02-2014

US generics major Mylan has launched the world's first trastuzumab biosimilar in India. The product,…

Asia-PacificBioconBiosimilarsGenericsHerceptinHertrazIndiaMarkets & MarketingMylan LaboratoriesOncologyRoche

MAb market for gastric and esophageal cancer expected to double by 2019

MAb market for gastric and esophageal cancer expected to double by 2019

18-01-2014

Due to favorable market conditions in terms of US pricing structures and the anticipated approval of…

BiotechnologyHerceptinMarkets & MarketingOncologyRoche

Celltrion’s trastuzumab biosimilar, Herzuma, approved in South Korea

16-01-2014

South Korean biopharmaceutical firm Celltrion has received approval for its cancer treatment biosimilar…

Asia-PacificBiosimilarsCellTrionGenericsHerceptinHerzumaOncologyRegulationRoche

Lung cancer treatment takes another forward step in New Zealand

Lung cancer treatment takes another forward step in New Zealand

09-01-2014

Improvements in lung cancer treatment are set to continue with a decision for New Zealand’s Pharmaceutical…

Asia-PacificAstraZenecaFinancialHealthcareIressaOncologyPharmaceuticalRocheTarceva

New Zealand funding plans for Tarceva and Revolade

New Zealand funding plans for Tarceva and Revolade

09-12-2013

Following a consultation, New Zealand’s Pharmaceutical Management Agency PHARMAC said this morning…

Asia-PacificGlaxoSmithKlineHematologyNew ZealandOncologyPharmaceuticalPricingRegulationRevoladeRocheTarceva

Mylan-Biocon Herceptin biosimilar gets first Indian approval

Mylan-Biocon Herceptin biosimilar gets first Indian approval

26-11-2013

US generic major Mylan says that its partner, India-based biotechnology firm Biocon has received approval…

Asia-PacificBioconBiosimilarsGenericsHerceptinHertrazMylan LaboratoriesOncologyRegulationRoche

Report: Tarceva and Iressa favored by European oncologists for NSCLC

Report: Tarceva and Iressa favored by European oncologists for NSCLC

04-11-2013

Oncologists across the top five European countries are prescribing Roche's Tarceva or AstraZeneca's Iressa…

AstraZenecaEuropeIressaOncologyPfizerPharmaceuticalPricingRegulationRocheTarcevaXalkori

More highlights from European Cancer Congress from Boehringer and Roche

More highlights from European Cancer Congress from Boehringer and Roche

30-09-2013

Roche presented new results from a trial of an investigational antibody which have shown encouraging…

Boehringer IngelheimEuropeHerceptinnintedanibOncologyPharmaceuticalResearchRoche

Roche's subcutaneous Herceptin injection approved for use in UK

Roche's subcutaneous Herceptin injection approved for use in UK

24-09-2013

From today HER2-positive breast cancer patients in the UK could benefit from a faster, more efficient…

EuropeHerceptinLicensingOncologyPharmaceuticalRoche

Roche's new timesaving formulation of Herceptin approved in Europe

02-09-2013

Swiss pharma major Roche (ROG: SIX) revealed this morning (September 2) that a new injectable (subcutaneous)…

BiotechnologyEuropeHerceptinOncologyPharmaceuticalRegulationRoche

US firms establish strategic partnership around biosimilars

06-08-2013

Privately-held Oncobiologics has formed a broad strategic partnership with fellow USA-based inVentiv…

AvastinBiotechnologyErbituxGenericsHerceptinHumiraImmunologicalsinVentive HealthOncobiologicsOncologyProductionResearchRituxan

Roche hopes Kadcyla will replace revenue lost by Herceptin patent expiry

02-08-2013

Swiss drug major Roche (ROG: SIX) could be hit by biosimilar versions of its breakthrough HER2-positive…

EuropeFinancialHerceptinKadcylaOncologyPharmaceuticalRoche

Mylan enters Tarceva settlement agreement

24-07-2013

US generics firm Mylan (Nasdaq: MYL) has entered into a settlement agreement with OSI Pharmaceuticals,…

GenentechGenericsLegalMylan LaboratoriesNorth AmericaOncologyOSI PharmaceuticalsPatentsPfizerTarceva

Turkey's NSCLC drug market forecast to expand at 7% a year through 2017

13-06-2013

From 2012 to 2017, the non-small-cell lung cancer (NSCLC) market in Turkey will increase at an annual…

AlimtaBiotechnologyEli LillyEuropeMarkets & MarketingOncologyPharmaceuticalRocheTarceva

US FDA approves companion diagnostic for Tarceva, and new indication for the Roche drug

15-05-2013

The US Food and Drug Administration late yesterday (May 14) approved Swiss drug major Roche (ROG: SIX)…

Boehringer IngelheimNorth AmericaOncologyPharmaceuticalQiagenRegulationRocheTarcevaTomtovok

1 to 25 of 59 results

Back to top